Novavax shares dive on yet another stumble in the hunt for an EUA, with FDA delay as US pauses funding
Rack up another delay for Novavax $NVAX on the crucial EUA front.
The biotech’s Q2 review dropped after the market close on Thursday, and with it came the news that their request for an emergency use approval of their Covid-19 vaccine at the FDA — already pushed back several times — would once again slip back another quarter, this time to Q4.
Company execs led by CEO Stan Erck downplayed the delay. But early Friday The New York Times flagged Novavax’s SEC filing, highlighting:
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,200+ biopharma pros reading Endpoints daily — and it's free.